Chronic kidney disease trials in Slovakia

In Slovakia 8 Also abroad 798

8 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Where
Kosice, Myjava, Nitra, Presov, Púchov, Trenčín, Trnava, Žilina
Age
18 years and over
People
5,000 worldwide
Run by
AstraZeneca
See details and how to joinNCT06742723 · EU 2023-506460-14-00
Phase 3Taking people
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Where
Bratislava, Galanta, Ilava, Petrzalka, Pezinok, Poprad, Stará Turá, Trenčín, Trstena, Zilina, Žilina
Age
50 years and over
People
7,140 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07241390 · EU 2025-523123-22-00
Phase 3Taking people
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Where
Košice
Age
18 years to 100 years
People
540 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04557462 · EU 2023-508690-92-00
Phase 2/3Taking people
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Where
Levice, Lučenec, Púchov
Age
18 years and over
People
3,110 worldwide
Run by
CSL Behring
See details and how to joinNCT05485961 · EU 2022-500273-14-00
Phase 3Taking people
Efepoetin alfa for treatment of anemia in chronic kidney disease on dialysis
Where
Bratislava, Galanta, Pezinok, Púchov, Sala, Zvolen
Age
18 years and over
People
337 worldwide
Run by
Genexine Inc.
See details and how to join2023-503634-50-01 · EU 2023-503634-50-01
Early phase 1Enrolling by invitation
The MIMIGA Study is a Randomized, Double-blind, Placebo-controlled Crossover Trial Evaluating the Safety and Efficacy of SCFA vs. Placebo. Administered Orally Once Daily With Standard Care, it Aims to Prevent CKD Progression in Biopsy-proven IgA Nephropathy by Modulating the Gut Microbiome.
Where
Martin
Age
18 years and over
People
120
Run by
University Hospital, Martin
See details and how to joinNCT07750249
No phaseTaking people
Physical Performance Assessment in Kidney Transplant Evaluation
Where
Martin
Age
18 years and over
People
50
Run by
University Hospital, Martin
See details and how to joinNCT07338929
Phase 3Enrolling by invitation
Silymarin's Advantage on Graft Effectiveness
Where
Martin
People
130
Run by
University Hospital, Martin
See details and how to joinNCT06801886